Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

Ka Lung Wu, Wessel Van Wieringen, Edo Vellenga, Sonja Zweegman, Henk M. Lokhorst, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.
Original languageEnglish
Pages (from-to)996-997
Number of pages2
JournalHaematologica
Volume90
Issue number7
Publication statusPublished - Jul 2005

Cite this